de Vries T J, van Muijen G N, Ruiter D J
Department of Pathology, University Hospital, Nijmegen, The Netherlands.
Pathol Res Pract. 1996 Jul;192(7):718-33. doi: 10.1016/S0344-0338(96)80094-X.
The involvement of proteases in the metastatic spread of tumour cells and in tumour related processes, such as angiogenesis and ulceration, has been known for many decades. This chapter reviews the involvement of one proteolytic system--the plasminogen activation system--in tumour progression. In recent years, many biochemical properties of the various components of the plasminogen activation system have become known. These properties and the functional relationship between the components are discussed in the first section. Since interfering with proteolysis by tumour cells and by newly formed endothelial cells can be an objective for future therapy, experimental tumour models have been used to study the effects of inhibitors of plasminogen activation. The second section deals with this issue. Finally, the presence of the various components of the plasminogen activation system in human tumours is reviewed. Following the availability of specific ELISAs, antibodies and molecular probes, the content and the cellular distribution of the components of the plasminogen activation system have recently been mapped in various human tumours.
几十年来,人们已经知道蛋白酶参与肿瘤细胞的转移扩散以及与肿瘤相关的过程,如血管生成和溃疡形成。本章回顾一种蛋白水解系统——纤溶酶原激活系统——在肿瘤进展中的作用。近年来,纤溶酶原激活系统各组分的许多生化特性已为人所知。第一部分讨论了这些特性以及各组分之间的功能关系。由于干扰肿瘤细胞和新形成的内皮细胞的蛋白水解作用可能成为未来治疗的目标,因此已使用实验性肿瘤模型来研究纤溶酶原激活抑制剂的作用。第二部分论述了这个问题。最后,回顾了纤溶酶原激活系统各组分在人类肿瘤中的存在情况。随着特异性酶联免疫吸附测定法、抗体和分子探针的出现,纤溶酶原激活系统各组分的含量和细胞分布最近已在各种人类肿瘤中得以明确。